To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
108 Current news of Qiagenrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
QIAGEN announced that Thierry Bernard has been named Chief Executive Officer. Additionally, a Joint Meeting of the Supervisory Board and the Managing Board has resolved to propose Mr. Bernard, who has been with QIAGEN since 2015, for election as Chief Executive Officer and a Managing Director at ...
QIAGEN announced that it has obtained derogation in Germany by the Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test to be sold as an in vitro diagnostic (“IVD”) for the detection of SARS-CoV-2. At the same time, the ...
QIAGEN announced plans to dramatically ramp up global production capacity of RNA extraction kits that are used as part of workflows around the world to detect nucleic acid from SARS-CoV-2, the novel coronavirus that causes COVID-19. QIAGEN has historically allocated global production capacity to ...
Thermo Fisher Scientific Inc. and QIAGEN N.V. announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the ...
QIAGEN N.V. announced that it has concluded the previously announced review of potential strategic alternatives, and has determined the execution of its current stand-alone business plan represents the best opportunity to drive future value creation. The Supervisory Board and Management Board of ...
Peer M. Schatz to step down as CEO
QIAGEN N.V. announced thatPeer M. Schatz, Chief Executive Officer, has notified the Company that, after 27 years at QIAGEN, he has decided to step down as Chief Executive Officer and Chairman of the Management Board. He will remain with QIAGEN as Special Advisor to the Supervisory Board and ...
Expanding clinical bioinformatics capabilities in molecular oncology
QIAGEN N.V. announced it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The addition of N-of-One will enable QIAGEN to significantly expand its ...
QIAGEN enters into agreement to acquire STAT-Dx
QIAGEN N.V. announced it has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next generation of multiplex diagnostics for one-step, fully integrated molecular analysis of common syndromes using a novel system based on real-time PCR technology and proven ...
QIAGEN pays Oxford Immunotec for royalty free license
QIAGEN N.V. and Oxford Immunotec Ltd. announced that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston alleging patent infringement in relation to QIAGEN’s QuantiFERON®-TB Gold and QuantiFERON®-TB Gold Plus products. Under terms ...
Aiding the analysis of hereditary disorders by integrating genomic and clinical databases
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and CENTOGENE AG announced a collaboration and co-marketing agreement to provide customers more complete Sample to Insight research and clinical testing solutions in rare genetic diseases. CENTOGENE is a leading rare disease company providing ...